

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXS1656

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUIDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional

options to display authors and affiliated organizations

NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in

NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:11:38 ON 03 JUL 2008

=> File Medline EMBASE Biosis Caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 18:11:52 ON 03 JUL 2008

FILE 'EMBASE' ENTERED AT 18:11:52 ON 03 JUL 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 18:11:52 ON 03 JUL 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 18:11:52 ON 03 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> S ((klk 8) or (kallikrein 8) or neuropsin or ovasin) (6A) (protease or peptidase or proteinase or enzyme (2A) activity)

L1 191 ((KLK 8) OR (KALLIKREIN 8) OR NEUROPSIN OR OVASIN) (6A) (PROTEAS
E OR PEPTIDASE OR PROTEINASE OR ENZYME (2A) ACTIVITY)

=> duplicate

ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove

ENTER L# LIST OR (END):l1

DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L1

L2 85 DUPLICATE REMOVE L1 (106 DUPLICATES REMOVED)

=> S (protease or peptidase or proteinase or enzyme (2A) activity) (6A) (METHOD OR ANALYSIS OR ANALYZE OR ANALYZED OR ANALYZING OR TEST OR TESTING OR TESTED OR DETERMINING OR DETERMINATION OR DETERMINE OR DETERMINED OR EVALUATE OR EVALUATION OR EVALUATED OR EVALUATION)

L3 38846 (PROTEASE OR PEPTIDASE OR PROTEINASE OR ENZYME (2A) ACTIVITY)
(6A) (METHOD OR ANALYSIS OR ANALYZE OR ANALYZED OR ANALYZING OR
TEST OR TESTING OR TESTED OR DETERMINING OR DETERMINATION OR
DETERMINE OR DETERMINED OR EVALUATE OR EVALUATION OR EVALUATED
OR EVALUATION)

=> s l2 and l3

L4 6 L2 AND L3

=> d l5 1-6 bib ab

L5 NOT FOUND

The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l4 1-6 bib ab

L4 ANSWER 1 OF 6 MEDLINE on STN

AN 97312794 MEDLINE

DN PubMed ID: 9169235

TI Crystallization and preliminary X-ray analysis of
neuropsin, a serine protease expressed in the limbic
system of mouse brain.

AU Kishi T; Kato M; Shimizu T; Kato K; Matsumoto K; Yoshida S; Shiosaka S;
Hakoshima T

CS Department of Molecular Biology, Nara Institute of Science and Technology
(NAIST), Japan.

SO Journal of structural biology, (1997 Apr) Vol. 118, No. 3, pp. 248-51.
Journal code: 9011206. ISSN: 1047-8477.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Priority Journals

EM 199706

ED Entered STN: 9 Jul 1997

Last Updated on STN: 3 Mar 2000

Entered Medline: 20 Jun 1997

AB Neuropsin (M(r) 25032) is a serine protease expressed
in the limbic system of mouse brain. It has been implicated in various
neurological processes including formation of memory and may be important
as a drug target in the treatment of epilepsy. The recombinant protein
was produced using a baculovirus expression system and was purified. Two
crystal forms were obtained by a hanging-drop vapor-diffusion method with
polyethylene glycol. Preliminary X-ray crystallographic analysis revealed
that crystal form I belongs to triclinic space group P1 with unit cell
dimensions a = 97.16 A, b = 97.12 A, c = 46.75 A and alpha = 99.17
degrees, beta = 99.77 degrees, gamma = 117.35 degrees. Self-rotation
function analysis of these data of form I indicates the position of a
noncrystallographic threefold axis. There are six molecules in the
crystallographic asymmetric unit. Crystal form II also belongs to
triclinic space group P1 but has unit cell dimensions of a = 38.40 A, b =
55.16 A, c = 65.37 A and alpha = 95.38 degrees, beta = 89.98 degrees,
gamma = 110.46 degrees with two molecules in the crystallographic
asymmetric unit. Form II has a noncrystallographic twofold axis.
Intensity data to 3.1 A resolution for form I and to 2.2 A resolution for
form II have been collected.

L4 ANSWER 2 OF 6 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

AN 2006:398347 BIOSIS

DN PREV200600398661

TI Methods and reagents for protease inhibition.
 AU Albrecht, Hugo [Inventor]; Hengst, Ulrich [Inventor]; Monard, Denis [Inventor]
 CS Riehen, Switzerland
 ASSIGNEE: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
 PI US 07029877 20060418
 SO Official Gazette of the United States Patent and Trademark Office Patents, (APR 18 2006)
 CODEN: OGUPE7. ISSN: 0098-1133.
 DT Patent
 LA English
 ED Entered STN: 9 Aug 2006
 Last Updated on STN: 9 Aug 2006
 AB There is provided a protease inhibitor and a method of inhibiting a protease selected from the group consisting of thrombin, chymotrypsin and neuropsin, by contacting the protease with an effective amount of a member of the phosphoethanolamine binding protein (PEBP) family.

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:1248277 CAPLUS
 DN 146:22551
 TI Random mutagenesis, screening and selection of protease variants with altered sensitivity to activity modulators
 IN Koltermann, Andre; Kettling, Ulrich; Haupts, Ulrich; Coco, Wayne; Tebbe, Jan; Votsmeier, Christian; Scheidig, Andreas
 PA Direvo Biotech AG, Germany
 SO Eur. Pat. Appl., 93pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1726643	A1	20061129	EP 2005-104543	20050527
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	US 20060269538	A1	20061130	US 2006-441635	20060526
	WO 2006125827	A1	20061130	WO 2006-EP62644	20060526
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1883696	A1	20080206	EP 2006-763303	20060526
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	EP 2005-104543	A	20050527		
	US 2005-685566P	P	20050527		
	US 2005-686021P	P	20050531		
	WO 2006-EP62644	W	20060526		
AB	The present invention provides a method for the selection of proteases				

with altered sensitivity to one or more activity-modulating substances. The method combines the provision of a protease library (i.e., phage display library) encoding polynucleotide sequences generated by using PCR mutagenesis, expression of the enzymes, screening of the library in the presence of one or several activity-modulating substances, selection of variants with altered sensitivity to one or several activity-modulating substances and isolation of those polynucleotide sequences that encode for the selected variants. In particular, mutant variants of human trypsin are disclosed.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:684183 CAPLUS
DN 146:2865
TI Activation and enzymatic characterization of recombinant human kallikrein 8
AU Kishi, Tadaaki; Cloutier, Sylvain M.; Kundig, Christoph; Deperthes, David; Diamandis, Eleftherios P.
CS Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, M5G 1X5, Can.
SO Biological Chemistry (2006), 387(6), 723-731
CODEN: BICHF3; ISSN: 1431-6730
PB Walter de Gruyter GmbH & Co. KG
DT Journal
LA English
AB Human kallikrein 8 (hK8), whose gene was originally cloned as the human ortholog of a mouse brain protease, is known to be associated with diseases such as ovarian cancer and Alzheimer's disease. Recombinant human pro-kallikrein 8 was activated with lysyl endopeptidase-conjugated beads. Amino-terminal sequencing of the activated enzyme demonstrated the cleavage of a 9-aa propeptide from the pro-enzyme. The substrate specificity of activated hK8 was characterized using synthetic fluorescent substrates. HK8 showed trypsin-like specificity, as predicted from sequence anal. and enzymic characterization of the mouse ortholog. All synthetic substrates tested containing either arginine or lysine at P1 position were cleaved by hK8. The highest kcat/Km value of 20+103 M-1 s-1 was observed with Boc-Val-Pro-Arg-7-amido-4-methylcoumarin. The activity of hK8 was inhibited by antipain, chymostatin, and leupeptin. The concentration for 50% inhibition by the best inhibitor, antipain, was 0.46 µM. The effect of different metal ions on the enzyme activity was analyzed. Whereas Na+ had no effect on hK8 activity, Ni2+ and Zn2+ decreased the activity and Ca2+, Mg2+, and K+ had a stimulatory effect. Ca2+ was the best activator, with an optimal concentration of approx. 10 µM.

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1020554 CAPLUS
DN 143:282218
TI Protease activity assay method by using polymeric membrane
IN Shiosaka, Sadao; Tamura, Hidenori
PA Nara Institute of Science and Technology, Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005253436	A	20050922	JP 2004-73625	20040315
PRAI	JP 2004-73625		20040315		

AB A assay method for measuring protease (especially, neuropsin) activity with higher sensitivity and fewer sample amount than the traditional solution method. The method includes processes of (1) the sample containing protease is stucked to a polymeric membrane, (2) the protease is reacted with the substrate specific to the protease and (3) the signal resulted from the reaction is measured.

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:172125 CAPLUS

DN 136:212778

TI Identification of a novel brain serine protease inhibitory protein-phosphoethanolamine binding protein and methods and reagents for protease inhibition for the treatment of neurological disorders

IN Albrecht, Hugo; Hengst, Ulrich; Monard, Denis

PA Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, Switz.

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018623	A2	20020307	WO 2001-EP10043	20010830
	WO 2002018623	A3	20021114		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2420832	A1	20020307	CA 2001-2420832	20010830
	AU 2002012184	A	20020313	AU 2002-12184	20010830
	EP 1315758	A2	20030604	EP 2001-980309	20010830
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004507471	T	20040311	JP 2002-522529	20010830
	US 20050037009	A1	20050217	US 2003-362642	20030224
	US 7029877	B2	20060418		
	US 20060177432	A1	20060810	US 2005-311974	20051219
PRAI	GB 2000-21497	A	20000901		
	WO 2001-EP10043	W	20010830		
	US 2003-362642	A1	20030224		

AB The present invention is based on the discovery of a novel serine protease inhibitory protein-phosphoethanolamine binding protein (PEBP). PEPB is identified by the detection of a novel thrombin inhibitory activity in the brain of protease nexin-1(-/-) mice, a gene knockout for the only known endogenous protease inhibitor protease nexin-1 that specifically interferes with thrombotic activity and is expressed in the brain. PEBP exerts inhibitory activity against several serine proteases including thrombin, neuropsin, and chymotrypsin, whereas trypsin, tissue type plasminogen activator, and elastase are not affected. PEBP immunoreactivity is found on the surface of Rat-1 fibroblast cells and although its sequence contains no secretion signal, PEBP-H6 can be

purified from the conditioned medium upon recombinant expression. The method of inhibiting a protease selected from the group consisting of thrombin, chymotrypsin and neuropsin, by contacting the protease with an effective amount of PEBP.